Krystal Biotech (KRYS) Change in Receivables (2023 - 2026)

Krystal Biotech has disclosed Change in Receivables across 4 years of filings, most recently posting $12.0 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 46.39% year-over-year to $12.0 million; the TTM figure through Jun 2026 stood at $27.3 million (up 233.37% YoY), while the FY2025 annual figure was $22.1 million, down 64.72% from the prior year.
• Change in Receivables came in at $12.0 million for Q2 2026 at Krystal Biotech, up from -$58000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $56.8 million in Q2 2024 to a low of -$5.9 million in Q3 2024.
• Average Change in Receivables over 4 years is $11.6 million, with a median of $7.8 million recorded in 2024.
• Year-over-year, Change in Receivables slumped 163.75% in 2024 and soared 401.78% in 2025.
• Over 4 years, Change in Receivables stood at $32.7 million in 2023, then tumbled by 77.24% to $7.4 million in 2024, then slumped by 133.45% to -$2.5 million in 2025, then soared by 580.46% to $12.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $12.0 million in Q2 2026, -$58000.0 in Q1 2026, and -$2.5 million in Q4 2025.